Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  1/25/2016
Medical Specialists Of Palm Beaches
mi
from
Lake Worth, FL
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 1/25/2016
Medical Specialists Of Palm Beaches
mi
from
Lake Worth, FL
Click here to add this to my saved trials
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  1/25/2016
Moffitt Cancer Center
mi
from
Tampa, FL
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 1/25/2016
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  1/25/2016
University Medical Center, Inc
mi
from
Louisville, KY
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 1/25/2016
University Medical Center, Inc
mi
from
Louisville, KY
Click here to add this to my saved trials
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  1/25/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 1/25/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  1/25/2016
Albert Einstein Cancer Center
mi
from
Bronx, NY
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 1/25/2016
Albert Einstein Cancer Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  1/25/2016
Virginia Mason Medical Center
mi
from
Seattle, WA
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 1/25/2016
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  1/25/2016
Providence Cancer Center
mi
from
Spokane, WA
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 1/25/2016
Providence Cancer Center
mi
from
Spokane, WA
Click here to add this to my saved trials
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  1/25/2016
Local Institution
mi
from
Capital Federal,
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 1/25/2016
Local Institution
mi
from
Capital Federal,
Click here to add this to my saved trials
Clinical Outcomes in Hereditary Cancer
Clinical Outcomes in Hereditary Cancer
Status: Enrolling
Updated:  1/27/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Clinical Outcomes in Hereditary Cancer
Clinical Outcomes in Hereditary Cancer
Status: Enrolling
Updated: 1/27/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
Randomized, Blinded Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and TNF-α Release
Status: Enrolling
Updated:  1/27/2016
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
Randomized, Blinded Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and TNF-α Release
Status: Enrolling
Updated: 1/27/2016
University of Kentucky, Markey Cancer Center
mi
from
Lexington, KY
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
21st Century Oncology - Carolina Regional Cancer Center
mi
from
Myrtle Beach, SC
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
21st Century Oncology - Carolina Regional Cancer Center
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Abington Memorial Hospital
mi
from
Abington, PA
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
AnMedical Health Cancer Center
mi
from
Anderson, SC
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
AnMedical Health Cancer Center
mi
from
Anderson, SC
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Arizona Cancer Center
mi
from
Scottsdale, AZ
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Arizona Cancer Center
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Cancer Care Northwest
mi
from
Spokane, WA
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Cancer Care Northwest
mi
from
Spokane, WA
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
CaroMont Health Comprehensive Cancer Center
mi
from
Gastonia, NC
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
CaroMont Health Comprehensive Cancer Center
mi
from
Gastonia, NC
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Columbia - St. Mary's
mi
from
Milwaukee, WI
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Columbia - St. Mary's
mi
from
Milwaukee, WI
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Hughes Cancer Center
mi
from
East Stroudsburg, PA
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Hughes Cancer Center
mi
from
East Stroudsburg, PA
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Ironwood Cancer and Research Centers
mi
from
Mesa, AZ
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Ironwood Cancer and Research Centers
mi
from
Mesa, AZ
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
John B. Amos Cancer Center
mi
from
Columbus, GA
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
John B. Amos Cancer Center
mi
from
Columbus, GA
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Lakeland Regional Cancer Center
mi
from
Lakeland, FL
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Lakeland Regional Cancer Center
mi
from
Lakeland, FL
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Mayo Clinic - LaCrosse
mi
from
LaCrosse, WI
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Mayo Clinic - LaCrosse
mi
from
LaCrosse, WI
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Mount Nittany Medical Center
mi
from
State College, PA
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Mount Nittany Medical Center
mi
from
State College, PA
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Norwalk Hospital
mi
from
Norwalk, CT
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Norwalk Hospital
mi
from
Norwalk, CT
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Parkview Research Center
mi
from
Fort Wayne, IN
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Parkview Research Center
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Radiation Oncology Associates - Parkview Research Center
mi
from
Fort Wayne, IN
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Radiation Oncology Associates - Parkview Research Center
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Sanford Health
mi
from
Bismarck, ND
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Sanford Health
mi
from
Bismarck, ND
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Sanford Research/USD
mi
from
Sioux Falls, SD
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Sanford Research/USD
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Spartanburg Regional Medical Center - Gibbs Cancer Center
mi
from
Spartanburg, SC
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Spartanburg Regional Medical Center - Gibbs Cancer Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
St. John Health System
mi
from
Tulsa, OK
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
St. John Health System
mi
from
Tulsa, OK
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
St. Vincent Anderson Regional Hospital Cancer Center
mi
from
Anderson, IN
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
St. Vincent Anderson Regional Hospital Cancer Center
mi
from
Anderson, IN
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
University of Colorado Hospital, Dept. of Radiation Oncology
mi
from
Aurora, CO
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
University of Colorado Hospital, Dept. of Radiation Oncology
mi
from
Aurora, CO
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
University of Nebraska Medical Center Eppley Cancer Center
mi
from
Omaha, NE
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
University of Nebraska Medical Center Eppley Cancer Center
mi
from
Omaha, NE
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated:  1/27/2016
Willis Knighton Cancer Center
mi
from
Shreveport, LA
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis
Status: Enrolling
Updated: 1/27/2016
Willis Knighton Cancer Center
mi
from
Shreveport, LA
Click here to add this to my saved trials
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated:  1/28/2016
Maricopa Integrated Health System
mi
from
Phoenix, AZ
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated: 1/28/2016
Maricopa Integrated Health System
mi
from
Phoenix, AZ
Click here to add this to my saved trials
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated:  1/28/2016
Providence Saint-Joseph Medical Center
mi
from
Burbank, CA
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated: 1/28/2016
Providence Saint-Joseph Medical Center
mi
from
Burbank, CA
Click here to add this to my saved trials
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated:  1/28/2016
Comprehensive Cancer Center
mi
from
Palm Springs, CA
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated: 1/28/2016
Comprehensive Cancer Center
mi
from
Palm Springs, CA
Click here to add this to my saved trials
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated:  1/28/2016
Breastlink
mi
from
Santa Ana, CA
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated: 1/28/2016
Breastlink
mi
from
Santa Ana, CA
Click here to add this to my saved trials
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated:  1/28/2016
Redwood Regional Cancer Center
mi
from
Santa Rosa, CA
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated: 1/28/2016
Redwood Regional Cancer Center
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated:  1/28/2016
Exempla Saint Joseph Hospital
mi
from
Denver, CO
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated: 1/28/2016
Exempla Saint Joseph Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated:  1/28/2016
The Stamford Hospital
mi
from
Stamford, CT
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated: 1/28/2016
The Stamford Hospital
mi
from
Stamford, CT
Click here to add this to my saved trials
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated:  1/28/2016
The Breast Institute at JFK Medical
mi
from
Atlantis, FL
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated: 1/28/2016
The Breast Institute at JFK Medical
mi
from
Atlantis, FL
Click here to add this to my saved trials
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated:  1/28/2016
Halifax Health- Center for Oncology
mi
from
Daytona Beach, FL
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated: 1/28/2016
Halifax Health- Center for Oncology
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated:  1/28/2016
Broward Health Medical Center
mi
from
Fort Lauderdale, FL
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated: 1/28/2016
Broward Health Medical Center
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated:  1/28/2016
Regional Breast/21st Century Oncology
mi
from
Fort Myers, FL
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated: 1/28/2016
Regional Breast/21st Century Oncology
mi
from
Fort Myers, FL
Click here to add this to my saved trials
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated:  1/28/2016
Northeast Georgia Cancer Care
mi
from
Athens, GA
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated: 1/28/2016
Northeast Georgia Cancer Care
mi
from
Athens, GA
Click here to add this to my saved trials
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated:  1/28/2016
Dekalb Medical Center
mi
from
Decatur, GA
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Status: Enrolling
Updated: 1/28/2016
Dekalb Medical Center
mi
from
Decatur, GA
Click here to add this to my saved trials